Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Integrating Data: Daiichi, Takeda Join Lifestyle Project To Inform R&D

Industry Has Called For Initiatives

Executive Summary

The data collected from wearable devices for a year will provide lifecycle data to a much long-termed study with various health data. The study will not only contribute to drug discovery and personalized healthcare by the firms in near future, but also suggests bigger goals by Japan’s healthcare industry.

You may also be interested in...



Japan’s All-Genome Project Hopes To Push Pharma R&D

Japan is aiming for the betterment of pharma R&D and medical services for rare disease patients by building a database connecting genome analysis data and clinical records. While several clinical studies are planned for the next couple of years, there are also concerns around the actual trickle-down of benefits to patients and data privacy.

Takeda Sees Mainstays Tiding It Over Upcoming Expiries

As Takeda reported what its CEO described as "a remarkable year," the company sees itself as well positioned to ride out the expiries over the next few years of exclusivity for several big-selling products, as it looks to mainstays and more organic growth to tide it over the "temporary headwinds."

Mainstays Give And Take As Major Japan Firms Report Results

While Daiichi Sankyo reveals ambitious plan with Enhertu, Chugai shows stable growth plans with COVID-19 drugs, Astellas reacted to concerns over Xtandi’s slow growth with enthusiastic investment plan for the next potential star.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC146463

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel